Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis

Prostate

Volumn 73, Issue 15, 2013, Pages 1636-1650

  Kumagai, Jinpei ^a   Hofland, Johannes ^a   Erkens Schulze, Sigrun ^a   Dits, Natasja F J ^a   Steenbergen, Jacobie ^a   Jenster, Guido ^a   Homma, Yukio ^b   De Jong, Frank H ^a   Van Weerden, Wytske M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

androgen independent prostate cancer; androgen responsive genes; precursors of testosterone; proliferation; real time RT PCR

Indexed keywords

ADRENAL ANDROGEN PRECURSOR; ANDROGEN RECEPTOR; ANDROSTENEDIOL; ANDROSTENEDIONE; ANTIANDROGEN; BICALUTAMIDE; FKBP5 PROTEIN; HORMONE PRECURSOR; PRASTERONE; PREGNENOLONE; PROGESTERONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TMPRSS2 PROTEIN; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ARTICLE; BIOSYNTHESIS; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRATUMORAL DRUG ADMINISTRATION; MALE; PRE T LYMPHOCYTE; PRIORITY JOURNAL; PROSTATE CANCER; RNA EXTRACTION; STEROIDOGENESIS; TESTOSTERONE BLOOD LEVEL; TRANSACTIVATION; TUMOR CELL LINE;

ANDROGEN-INDEPENDENT PROSTATE CANCER; ANDROGEN-RESPONSIVE GENES; PRECURSORS OF TESTOSTERONE; PROLIFERATION; REAL-TIME RT-PCR;

ANDROGENS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE;

EID: 84884901525     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22655     Document Type: Article

References (60)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Malvezzi M, Arfe A, Bertuccio P, Levi F, La Vecchia C, Negri E,. European cancer mortality predictions for the year 2011. Ann Oncol 2011; 22 (4): 947-956.
3. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL III, Bennett CL, Scher HI,. American Society of Clinical O. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25 (12): 1596-1605.
4. Huggins C, Hodges CV,. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22 (4): 232-240.
5. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI,. Investigators C-A-. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 (21): 1995-2005.
6. Molina A, Belldegrun A,. Novel therapeutic strategies for castration resistant prostate cancer: Inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 2011; 185 (3): 787-794.
7. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS,. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28 (9): 1489-1495.
8. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23 (32): 8253-8261.
9. Yuan X, Balk SP,. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 2009; 27 (1): 36-41.
10. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL,. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164 (1): 217-227.
11. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, Trapman J,. Androgen receptors in endocrine-therapy- resistant human prostate cancer. Int J Cancer 1991; 48 (2): 189-193.
12. Labrie F, Dupont A, Belanger A,. Complete androgen blockade for the treatment of prostate cancer. Important Adv Oncol 1985; 193-217.
13. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T,. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61 (9): 3550-3555.
14. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ,. Cancer Leukemia Group BS. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21 (14): 2673-2678.
15. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS,. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008; 68 (11): 4447-4454.
16. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS,. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10 (2): 440-448.
17. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL,. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005; 11 (13): 4653-4657.
18. Mostaghel EA, Nelson PS,. Intracrine androgen metabolism in prostate cancer progression: Mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 2008; 22 (2): 243-258.
19. Luu The V, Lachance Y, Labrie C, Leblanc G, Thomas JL, Strickler RC, Labrie F,. Full length cDNA structure and deduced amino acid sequence of human 3 beta-hydroxy-5-ene steroid dehydrogenase. Mol Endocrinol 1989; 3 (8): 1310-1312.
20. Luu-The V, Labrie C, Zhao HF, Couet J, Lachance Y, Simard J, Cote J, Leblanc G, Lagace L, Berube D, Gagne R, Labrie F,. Purification, cloning, complementary DNA structure, and predicted amino acid sequence of human estradiol 17 beta-dehydrogenase. Ann N Y Acad Sci 1990; 595: 40-52.
21. Auchus RJ,. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004; 15 (9): 432-438.
22. Harper ME, Pike A, Peeling WB, Griffiths K,. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol 1974; 60 (1): 117-125.
23. El-Alfy M, Luu-The V, Huang XF, Berger L, Labrie F, Pelletier G,. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology 1999; 140 (3): 1481-1491.
24. Fung KM, Samara EN, Wong C, Metwalli A, Krlin R, Bane B, Liu CZ, Yang JT, Pitha JV, Culkin DJ, Kropp BP, Penning TM, Lin HK,. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006; 13 (1): 169-180.
25. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H, Nishiyama T, Takahashi K, Hamakubo T, Kodama T, Naito M,. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008; 61 (4): 448-454.
26. Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, Jenster G, Schroder FH, de Jong FH,. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 2010; 70 (3): 1256-1264.
27. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP,. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66 (5): 2815-2825.
28. Twiddy AL, Leon CG, Wasan KM,. Cholesterol as a potential target for castration-resistant prostate cancer. Pharm Res 2011; 28 (3): 423-437.
29. Locke JA, Nelson CC, Adomat HH, Hendy SC, Gleave ME, Guns ES,. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. J Steroid Biochem Mol Biol 2009; 115 (3-5): 126-136.
30. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC,. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68 (15): 6407-6415.
31. Dillard PR, Lin MF, Khan SA,. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 2008; 295 (1-2): 115-120.
32. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G,. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 2006; 66 (10): 5012-5020.
33. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E,. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992; 41 (3-8): 665-669.
34. van Weerden WM, de Ridder CM, Verdaasdonk CL, Romijn JC, van der Kwast TH, Schroder FH, van Steenbrugge GJ,. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 1996; 149 (3): 1055-1062.
35. Romijn JC, Verkoelen CF, Schroeder FH,. Application of the MTT assay to human prostate cancer cell lines in vitro: Establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 1988; 12 (1): 99-110.
36. Takizawa I, Nishiyama T, Hara N, Hoshii T, Ishizaki F, Miyashiro Y, Takahashi K,. Trilostane, an inhibitor of 3beta-hydroxysteroid dehydrogenase, has an agonistic activity on androgen receptor in human prostate cancer cells. Cancer Lett 2010; 297 (2): 226-230.
37. Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N,. 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology 2010; 151 (8): 3514-3520.
38. Day JM, Purohit A, Tutill HJ, Foster PA, Woo LW, Potter BV, Reed MJ,. The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy. Ann N Y Acad Sci 2009; 1155: 80-87.
39. Klein H, Molwitz T, Bartsch W,. Steroid sulfate sulfatase in human benign prostatic hyperplasia: Characterization and quantification of the enzyme in epithelium and stroma. J Steroid Biochem 1989; 33 (2): 195-200.
40. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon N, Wang H, Balk SP,. Intratumoral de novo steroid synthesis activates androgen receptor in castration resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011; 71 (20): 6503-6513.
41. Belanger A, Candas B, Dupont A, Cusan L, Diamond P, Gomez JL, Labrie F,. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab 1994; 79 (4): 1086-1090.
42. de Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F,. Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 1991; 51 (19): 5165-5170.
43. Byrns MC, Mindnich R, Duan L, Penning TM,. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5alpha-reductase inhibitor finasteride. J Steroid Biochem Mol Biol 2012; 130 (1-2): 7-15.
44. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E,. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173 (2): 534-540.
45. Grigoryev DN, Long BJ, Njar VC, Brodie AH,. Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. J Steroid Biochem Mol Biol 2000; 75 (1): 1-10.
46. Arai S, Miyashiro Y, Shibata Y, Tomaru Y, Kobayashi M, Honma S, Suzuki K,. Effect of castration monotherapy on the levels of adrenal androgens in cancerous prostatic tissues. Steroids 2011; 76 (3): 301-308.
47. Samson M, Labrie F, Luu-The V,. Sequential transformation of 4-androstenedione into dihydrotestosterone in prostate carcinoma (DU-145) cells indicates that 4-androstenedione and not testosterone is the substrate of 5a-reductase. Horm Mol Biol Clin Investig 2009; 1 (2): 67-72.
48. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N,. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci USA 2011; 108 (33): 13728-13733.
49. Samson M, Labrie F, Zouboulis CC, Luu-The V,. Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as an intermediate in the SZ95 sebaceous gland cell line. J Invest Dermatol 2010; 130 (2): 602-604.
50. Luu-The V,. Assessment of steroidogenic pathways that do not require testosterone as intermediate. Horm Mol Biol Clin Invest 2011; 5 (3): 161-165.
51. Miyamoto H, Yeh S, Lardy H, Messing E, Chang C,. Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 1998; 95 (19): 11083-11088.
52. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M,. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004; 64 (2): 765-771.
53. Chen F, Knecht K, Leu C, Rutledge SJ, Scafonas A, Gambone C, Vogel R, Zhang H, Kasparcova V, Bai C, Harada S, Schmidt A, Reszka A, Freedman L,. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol. J Steroid Biochem Mol Biol 2004; 91 (4-5): 247-257.
54. Fankhauser M, Amiry N, Hong MKH, Dundee P, Chua J, Kerger M, Haviv I, Costello AJ, Corcoran NM, Hovens CM,. Androstenedione is the most efficient precursor of intraprostatic testosterone production in primary human prostate cancer tissue. Eur Urol Suppl 2011; 10 (2): abstract 631.
55. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS,. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26 (28): 4563-4571.
56. Hill M, Lukac D, Lapcik O, Sulcova J, Hampl R, Pouzar V, Starka L,. Age relationships and sex differences in serum levels of pregnenolone and 17-hydroxypregnenolone in healthy subjects. Clin Chem Lab Med 1999; 37 (4): 439-447.
57. Nishiyama T, Hashimoto Y, Takahashi K,. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 2004; 10 (21): 7121-7126.
58. Heracek J, Hampl R, Hill M, Starka L, Sachova J, Kuncova J, Eis V, Urban M, Mandys V,. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids 2007; 72 (4): 375-380.
59. Belanger A, Brochu M, Cliche J,. Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. J Clin Endocrinol Metab 1986; 62 (5): 812-815.
60. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI,. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56 (6): 1021-1024.